175 related articles for article (PubMed ID: 37238150)
41. The application of circulating tumor cell and cell-free DNA liquid biopsies in ovarian cancer.
Balla A; Bhak J; Biró O
Mol Cell Probes; 2022 Dec; 66():101871. PubMed ID: 36283501
[TBL] [Abstract][Full Text] [Related]
42. Stability of circulating miRNA in saliva: The influence of sample associated pre-analytical variables.
Romani C; Baronchelli M; Assoni C; Mattavelli D; Calza S; Piazza C; Bossi P
Clin Chim Acta; 2024 Jan; 553():117702. PubMed ID: 38097127
[TBL] [Abstract][Full Text] [Related]
43. Detection of HTLV-1 proviral DNA in cell-free DNA: Potential for non-invasive monitoring of Adult T cell leukaemia/lymphoma using liquid biopsy?
Joris T; Haddow J; Taylor GP; Cook LBM; Rowan AG
Front Immunol; 2023; 14():1150285. PubMed ID: 37114063
[TBL] [Abstract][Full Text] [Related]
44. Current and Future Perspectives of Cell-Free DNA in Liquid Biopsy.
Liu S; Wang J
Curr Issues Mol Biol; 2022 Jun; 44(6):2695-2709. PubMed ID: 35735625
[TBL] [Abstract][Full Text] [Related]
45. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing.
Deans ZC; Butler R; Cheetham M; Dequeker EMC; Fairley JA; Fenizia F; Hall JA; Keppens C; Normanno N; Schuuring E; Patton SJ
Virchows Arch; 2019 Jun; 474(6):681-689. PubMed ID: 31028539
[TBL] [Abstract][Full Text] [Related]
46. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
[TBL] [Abstract][Full Text] [Related]
47. The art of obtaining a high yield of cell-free DNA from urine.
Augustus E; Van Casteren K; Sorber L; van Dam P; Roeyen G; Peeters M; Vorsters A; Wouters A; Raskin J; Rolfo C; Zwaenepoel K; Pauwels P
PLoS One; 2020; 15(4):e0231058. PubMed ID: 32251424
[TBL] [Abstract][Full Text] [Related]
48. Cell free DNA: revolution in molecular diagnostics - the journey so far.
Nandi K; Verma R; Dawar R; Goswami B
Horm Mol Biol Clin Investig; 2020 Feb; 41(1):. PubMed ID: 32083442
[TBL] [Abstract][Full Text] [Related]
49. Targeted deep sequencing of cell-free DNA in serous body cavity fluids with malignant, suspicious, and benign cytology.
Yang SR; Mooney KL; Libiran P; Jones CD; Joshi R; Lau HD; Stehr H; Berry GJ; Zehnder JL; Long SR; Kong CS; Kunder CA
Cancer Cytopathol; 2020 Jan; 128(1):43-56. PubMed ID: 31751001
[TBL] [Abstract][Full Text] [Related]
50. The Utility of Repetitive Cell-Free DNA in Cancer Liquid Biopsies.
Gezer U; Bronkhorst AJ; Holdenrieder S
Diagnostics (Basel); 2022 Jun; 12(6):. PubMed ID: 35741173
[TBL] [Abstract][Full Text] [Related]
51. Optimized (Pre) Analytical Conditions and Workflow for Droplet Digital PCR Analysis of Cell-Free DNA from Patients with Suspected Lung Carcinoma.
de Kock R; Deiman B; Kraaijvanger R; Scharnhorst V
J Mol Diagn; 2019 Sep; 21(5):895-902. PubMed ID: 31229652
[TBL] [Abstract][Full Text] [Related]
52. Cell-Free DNA Fragmentomics in Liquid Biopsy.
Ding SC; Lo YMD
Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35454026
[TBL] [Abstract][Full Text] [Related]
53. Liquid biopsy in CNS tumors: Current status & future perspectives.
Husain N; Husain A; Mishra S; Srivastava P
Indian J Pathol Microbiol; 2022 May; 65(Supplement):S111-S121. PubMed ID: 35562141
[TBL] [Abstract][Full Text] [Related]
54. Liquid biopsy as a tool for predicts of severe COVID-19 and hospitalised community-acquired pneumonia.
Komarevtseva I; Ihnatova A; Rudenko I; Balabanova K; Komarevtsev V
Pol Merkur Lekarski; 2022 Jun; 50(297):155-159. PubMed ID: 35801596
[TBL] [Abstract][Full Text] [Related]
55. Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer.
Zhang X; Ju S; Wang X; Cong H
Clin Exp Med; 2019 Aug; 19(3):271-279. PubMed ID: 31190187
[TBL] [Abstract][Full Text] [Related]
56. Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.
Bos MK; Angus L; Nasserinejad K; Jager A; Jansen MPHM; Martens JWM; Sleijfer S
Cancer Treat Rev; 2020 Feb; 83():101951. PubMed ID: 31874446
[TBL] [Abstract][Full Text] [Related]
57. Circulating DNA and Liquid Biopsies in the Management of Patients with Cancer.
Joosse SA; Pantel K
Cancer Res; 2022 Jun; 82(12):2213-2215. PubMed ID: 35702889
[TBL] [Abstract][Full Text] [Related]
58. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.
Koeppel F; Blanchard S; Jovelet C; Genin B; Marcaillou C; Martin E; Rouleau E; Solary E; Soria JC; André F; Lacroix L
PLoS One; 2017; 12(11):e0188174. PubMed ID: 29161279
[TBL] [Abstract][Full Text] [Related]
59. Extracellular Vesicle-Derived DNA vs. CfDNA as a Biomarker for the Detection of Colon Cancer.
Thakur K; Singh MS; Feldstein-Davydova S; Hannes V; Hershkovitz D; Tsuriel S
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440345
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of pre-analytical factors affecting plasma DNA analysis.
Markus H; Contente-Cuomo T; Farooq M; Liang WS; Borad MJ; Sivakumar S; Gollins S; Tran NL; Dhruv HD; Berens ME; Bryce A; Sekulic A; Ribas A; Trent JM; LoRusso PM; Murtaza M
Sci Rep; 2018 May; 8(1):7375. PubMed ID: 29743667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
